SpliceBio Signs an Exclusive Collaboration and License Agreement with Spark Therapeutics to Develop Gene Therapy
Shots:
- SpliceBio will be eligible to receive up front, opt-in, and milestones of ~$216M along with royalties on net sales
- Spark to get an exclusive right globally to develop, manufacture, and commercialize a gene therapy arising from this research collaboration targeting an undisclosed inherited retinal disease
- The collaboration focuses on developing a gene therapy for an undisclosed inherited retinal disease using SpliceBio's Protein Splicing platform. Additionally, Spark is working to create capabilities and a pipeline of wholly-owned gene therapy programs as well as to advance its lead program for the treatment of Stargardt disease
Ref: PR Newswire | Image: SpliceBio
Related News:- Spark Therapeutics Signs an Option Agreement with Senti Bio to Develop Precision Gene Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
